The present study aimed to assess in a large study population of patients admitted for AD or ACLF: 1) copeptin as a prognostic biomarker of short-term survival and disease progression; and 2) whether copeptin might be of additional prognostic value to conventional prognostic scoring systems in cirrhosis and ACLF. This evidence concerns the gene AVP and Alzheimer disease.